Hims & Hers (NYSE:HIMS) announced plans to expand its digital health and weight loss services to Canada in 2026, coinciding with the first global availability of generic semaglutide.
Beginning in January 2026, Canada will become the first country to offer generic versions of semaglutide, a GLP-1 receptor agonist widely used for weight management under brand names such as Wegovy and Ozempic.
The development follows the expiration of patent and data exclusivity protections held by Novo Nordisk, opening the market to more affordable alternatives.
Hims & Hers will provide Canadian patients with access to these generics through its digital platform, which offers 24/7 consultations with licensed healthcare providers and personalized care plans.
According to the company, this model is intended to combine affordability with continuous, evidence-based support.
Currently, branded versions of semaglutide without clinical guidance cost more than C$200 per month in Canada.
Generic versions are expected to be available at a lower cost, potentially expanding access to treatment for the estimated two-thirds of Canadian adults affected by overweight or obesity, Hims & Hers said.
“Canada is a major opportunity to show what affordable, high-quality weight loss care can look like,” Hims & Hers CEO Andrew Dudum said.
“As generic semaglutide becomes available for the first time globally, we’re focused on making it truly accessible, by combining affordability with trusted, personalized care at scale.”
This expansion follows the company's recent acquisition of ZAVA, a European digital health platform, and is positioned as part of a broader strategy to grow its international footprint and improve care accessibility.
Hims & Hers shares added 0.7% at about $49 in the early afternoon on Wednesday, having more than doubled so far in 2025.